Wafik El-Deiry: Enjoyable interview with Benjamin Troth about what precision oncology has to offer in 2024
Wafik El-Deiry shared a post on LinkedIn:
“Enjoyable interview with Brown University Biotechnology Masters student Benjamin Troth.
We spoke about what precision oncology has to offer patients with cancer in 2024, challenges in heterogeneity and how the future is shaping up in the coming years including imagining solutions both that are currently feasible and some that might sound like sci-fi that don’t currently exist.”
Source: Wafik El-Deiry/LinkedIn
Wafik S. El-Deiry, MD, PhD, FACP, FRSM, is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center at Brown University and Director of the Joint Program in Cancer Biology at Brown University and affiliated hospitals.
He is the Editor in Chief at Oncotarget. Dr. El-Deiry discovered p21(WAF1) as a p53 target gene, cell cycle inhibitor, and tumor suppressor that explained the mammalian cell stress response. Dr. El-Deiry’s research is focused on mechanisms of therapy resistance with major efforts in drug discovery and development.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023